



LET YOUR COLLEAGUES KNOW

**Trainers' blog**

"Development of new medicines is extremely complex. It requires highly skilled experts in many disciplines who have state-of-the-art knowledge and can reliably contribute to enhance quality and efficiency of this process, based on their thorough education, their experience at the workplace and permanently updated know-how. In addition to the academic training in Universities Learned Societies can support lifelong personal development with practice-oriented training courses delivered by their highly experienced members. Therefore PharmaTrain combines training by Universities and Learned Societies."

Ingrid Klingmann, Deputy Coordinator of PharmaTrain project, European Forum for Good Clinical Practices EFGCP

Lifelong learning is an objective of any learned society such as EFGCP. There are 13 learned societies contributing to PharmaTrain. They too make their members aware of this new learning opportunities.

To foster your Continuing Professional Development in your lifelong learning, experts from industry and academia have developed a pan-European multi-centric modular platform at high quality standards. You should benefit from it – for your own career – by selecting

To all Alumni

You may have already been trained in one or the other training programme in medicines development and you may remember that you have been attracted to participate by a colleague of yours, on Alumni/on Alumna. Such training has paved many careers. We kindly ask you to make now your colleagues aware of our new standardized PharmaTrain Network with 14 University Centers in Europe – simply by word of mouth.

some of the modules or integrated modular programmes. You have plenty of choices via www.pharmatrain.eu for personalized learning/training.

Role of Universities

In the process of developing a medicine for patient use, Universities are traditionally involved in three areas: in early discovery and pharmaceutical research, in clinical pharmacology – today often called translational medicines 'from molecule to proof of concept' – as well as in clinical trials as clinical investigators. This includes the training thereof for future jobs in the pharmaceutical industry and academia. So far graduate training does rarely provide an overview of the entire value chain from molecule to patient use of a medicine.



There is a new role for Universities to provide such training optimally together with academics from industry with their particular expertise. The PharmaTrain partnership of 15 private pharmaceutical companies and 23 public Universities has done exactly that – a high quality network with shared standards and criteria. This should also enhance

**Industry's Voice**

"The pharmaceutical industry continues to experience unprecedented change and the rate of change is increasing. Therefore, continuous professional development is an absolute necessity. If you look in the mirror you will see the person who is responsible for your career development. However, you can't do this alone, others can help. Seize the opportunity and use the PharmaTrain courses. These have been developed specifically to address industry needs. Develop your competency portfolio and keep one step ahead of the others."

Mike Hardman, Co-Coordinator of PharmaTrain project, AstraZeneca

the expensive and extensive process to bring better and safer medicines to patients. European Universities together with industry take lead supported by the European Commission. This never happened before.

Fritz R. Bühler, Coordinator of PharmaTrain project, University of Basel

More infos: www.pharmatrain.eu

